Document text
Principal Investigator: Kathryn M. Anastos
Organization: ALBERT EINSTEIN COLLEGE OF MEDICINE
Fiscal Year: 2019
Award: $70,819
Funding agency: National Cancer Institute
Investigations of HPV related malignancies are heavily dependent on laboratory testing, both to measure the
outcomes (cancer, pre-cancer, intraepithelial neoplasia) and to define the possible predictors (e.g. high-risk
HPV types). Several new molecular diagnostic tests are becoming available, including HPV genotypes and
E6/E7 molecular testing, that can be performed in lower resource settings. Thus the development of Rwanda
as a regional hub for HPV/HIV translational research requires rigorous skills in histopathology and in flexible
platforms for molecular testing. The Consortium proposes major studies on cervical cancer screening in
HIV-positive women, and anal and penile prevalence of HPV in HIV-positive and -negative men who have
sex with men (MSM). We also project pilot projects investigating other HPV related malignancies—e.g.
squamous cell carcinoma of the conjunctiva (SCCC) and head and neck (SCCHN), as well as studying anal
HPV in HIV+ women, and oral-genital concordance of HPV types found in HIV+ and negative MSM. With
capacity building, much of the necessary laboratory testing can be done in Africa. We will develop a shared
resource in laboratory support for HPV related research, both in histopathology and in molecular testing.,
including several promising, highly specific new biomarkers that have been reported in HIV-negative women
including 1) E6/E7 HPV viral oncoprotein detection (which showed promising results in our large studies in
China) and 2) Ki-67 and Topo2a mRNA. We will also establish a PCR lab for HPV genotyping, important
now in assessing cervical and anal cancers, and in the future for monitoring and evaluation of vaccine impact
in HIV-infected and -uninfected women. The PCR lab will support all Consortium projects: cervical, anal, and
potential pilot projects of oral HPV and head and neck cancers.
Drs. Tiffany Hebert and Joel Palefsky will direct the Shared Resources Core. Dr. Hebert will continue to lead
the pathology capacity building. Dr. Palefsky will direct the development of the new molecular diagnostic
testing capabilities.
Terms: <AIDS Virus><AIDS associated cancer><AIDS related cancer><AIDS-Related Malignancy><AIDS-Related Malignant Neoplasm><AIDS-associated malignancies><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Africa><African><Algorithms><Anal><Anti-HIV Positivity><Anus><Biological Markers><Body Tissues><Cancer Cause><Cancer Etiology><Cancers><Cervical><Cervical Cancer Screening><Cervical Carcinoma><Cervix><Cervix Uteri><Cervix Uteri Carcinoma><Cervix carcinoma><China><Conjunctival Epidermoid Carcinoma><Conjunctival Squamous Cell Carcinoma><Detection><Development><Diagnosis><Disease><Disorder><Epithelial Dysplasia><Equipment><Foundations><Future><Genital><Genital system><Genotype><HIV><HIV Positive><HIV Positivity><HIV Seroconversion><HIV Seronegativities><HIV Seronegativity><HIV Seropositivity><HIV antibody positive><HIV negative><HIV-Associated Cancer><HIV-associated malignancy><HIV-related malignancy><HIV/AIDS-associated malignancy><HIV/AIDS-related cancer><HPV><HPV Vaccination><HPV-High Risk><HPV-Related Malignancy><HPV-associated cancer><HPV-associated malignancy><HPV-related cancer><HTLV-III Seroconversion><HTLV-III Seronegativities><HTLV-III Seronegativity><HTLV-III Seropositivity><Head and Neck><Head and Neck Cancer><Head and neck structure><Healthcare Delivery><High Prevalence><High Risk Oncogenic HPV><High risk HPV><High risk Human Papillomavirus><High risk Human papilloma virus><Histopathology><Human Immunodeficiency Viruses><Human Papilloma Virus><Human Papilloma Virus Vaccination><Human Papilloma Virus-Related Malignancy><Human Papilloma Virus-Related Malignant Neoplasm><Human Papilloma Virus-associated cancer><Human Papilloma Virus-associated malignancy><Human Papilloma Virus-related cancer><Human Papillomavirus><Human Papillomavirus Vaccination><Human Resources><Human papillomavirus-Related Malignancy><Human papillomavirus-Related Malignant Neoplasm><Incidence><Infectious Human Wart Virus><Infrastructure><Intraepithelial Neoplasia><Intraepithelial Neoplasms><Investigation><LAV-HTLV-III><Laboratories><Lateral><Lead><Lymphadenopathy-Associated Virus><MSM><Mainland China><Malignant Head and Neck Neoplasm><Malignant Neoplasms><Malignant Tumor><Manpower><Measures><Messenger RNA><Military Hospitals><Molecular><Molecular Diagnostic Testing><Monitor><Morbidity><Morbidity - disease rate><Oncogene Products><Oncogene Proteins><Oncoproteins><Oral><Outcome><Outcome Measure><Pathogenesis><Pathologist><Pathology><Pb element><Pilot Projects><Polymerase Chain Reaction><Population><Prevalence><Prevention program><Procedures><Public Health><Quality Control><Reporting><Research><Research Resources><Resource Sharing><Resources><Ruanda><Rwanda><TOP2><TOP2A><TOP2A gene><TP2A><Technology><Testing><Tissues><Training><Translational Research><Translational Science><Treatment Cost><Uterine Cervix><Uterine Cervix Carcinoma><Viral><Viral load measurement><Virus-HIV><Woman><anal and cervical cancer><bio-markers><biologic marker><biomarker><cancer prevention><cervical and anal cancer><cervical cancer early detection><cervical cancer prevention><conjunctiva><conjunctiva epidermoid carcinoma><conjunctiva squamous cell carcinoma><developmental><flexibility><flexible><health care delivery><health services delivery><heavy metal Pb><heavy metal lead><improved><mRNA><malignancy><malignant head and neck tumor><men><men who have sex with men><men who have sex with other men><men's><mortality><neoplasm/cancer><oral HPV><personnel><pilot study><predictive biomarkers><predictive marker><predictive molecular biomarker><programs><screening><skills><success><translation research><treatment program><unnecessary treatment><vaccine evaluation><vaccine screening><vaccine testing><virus load><wart virus>